Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ELVN vs DNTH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ELVN Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 4–3 Matrix Metrics)

ELVN Overall Winner 6-Pillar Tally: ELVN 2 – 1 DNTH (3 Tie) Matrix Metrics: ELVN 4 – 3 DNTH

As of Nov 16, 2026, Enliven Therapeutics, Inc. (ELVN) is the stronger overall head-to-head candidate over Dianthus Therapeutics, Inc. (DNTH) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). ELVN carries a Unified Composite Score of 35.9/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin), whereas DNTH carries 34.1/100 (SELL) at $88.58 (N/M Forward P/E, -8683.9% operating margin).

  • Growth vs. Quality Trade-Off: ELVN earns the overall head-to-head edge with a stronger Unified Composite Score (35.9/100 SELL vs. DNTH 34.1/100 SELL) and 0.96β · 60% Vol risk profile, whereas DNTH leads top-line expansion (+205.6% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although ELVN compares more favorably head-to-head, both ELVN (35.9/100 SELL) and DNTH (34.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ELVN vs DNTH
ELVN NASDAQ Head-to-Head Winner
Enliven Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$47.54
-2.58% 1D
Market Cap $3.6B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.96β · 60% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 15.0 Fund 42.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.3 · SMA20: $45.78 · SMA50: $46.20
DNTH NASDAQ
Dianthus Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$88.58
-3.52% 1D
Market Cap $5.2B
TTM Revenue $2.7M
Forward P/E N/M
Beta / 30D Vol 1.03β · 41% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 8.0 Fund 43.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.1 · SMA20: $84.01 · SMA50: $88.08

6-Pillar Scorecard Institutional Category Breakdown (ELVN 2 – 1 DNTH)

Columns: Metric · ELVN · DNTH
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale DNTH
Revenue Growth (YoY) +0.0% +205.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $2.7M
Market Cap $3.6B $5.2B
3. Profitability & Quality ELVN
Gross Margin N/A 100.0%
Operating Margin 0.0% -8683.9%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -16.8% -22.6%
4. Balance Sheet & Cash Flow ELVN
Cash Generation (TTM) -$66M -$176M
Cash Flow Margin N/A N/A
Net Cash / Leverage $150M Net Cash $54M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 46.9% (5th %ile) 83.5% (7th %ile)
Put/Call OI Skew 1.67x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ELVN (4) vs DNTH (3)
Institutional Metric ELVN DNTH Criterion Row Edge
Market Capitalization
Scale
$3.6B $5.2B Larger Scale DNTH
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +205.6% Higher Growth DNTH
Operating Margin (TTM)
Profitability
0.0% -8683.9% Higher Margin ELVN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-16.8% -22.6% Higher ROE ELVN
52-Week Range Position
Momentum
69% ($15–$62) 65% ($34–$118) Stronger Trend ELVN
Beta / 30D Volatility
Risk Regime
0.96β · 60% Vol 1.03β · 41% Vol Lower Realized Risk DNTH
Unified Institutional Score
Composite Signal
35.9 / 100 (SELL) 34.1 / 100 (SELL) Higher Composite ELVN
Trailing 12M Revenue (USD)
Operating Scale
N/A $2.7M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$66M ($150M Net Cash) -$176M ($54M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ELVN +4.51 pp
ELVN: +27.38% · DNTH: +22.87%
3M Horizon ELVN +2.48 pp
ELVN: -20.86% · DNTH: -23.34%
6M Horizon ELVN +14.01 pp
ELVN: +19.96% · DNTH: +5.95%
1Y Horizon DNTH +14.98 pp
ELVN: +134.53% · DNTH: +149.51%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELVN vs DNTH. Trailing 12-month operating profitability (ELVN 0.0% vs DNTH -8683.9%) and valuation multiples (ELVN N/M vs DNTH N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ELVN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-16.8% · N/M
DNTH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.7M
Gross Margin100.0%
Op. Margin-8683.9%
ROE / Fwd P/E-22.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ELVN CONSOLIDATION
59d in phase · OBV NEUTRAL
Current IV 46.9%
IV Percentile 5th %ile
Put/Call OI Skew 1.67x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ELVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DNTH CONSOLIDATION
149d in phase · OBV ACCUMULATION
Current IV 83.5%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DNTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ELVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.6B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DNTH Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.2B market capitalization and -8683.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ELVN vs DNTH Key Questions & Quantitative Answers

As of Nov 16, 2026, Enliven Therapeutics, Inc. (ELVN) is the stronger overall head-to-head candidate over Dianthus Therapeutics, Inc. (DNTH) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). ELVN carries a Unified Composite Score of 35.9/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin), whereas DNTH carries 34.1/100 (SELL) at $88.58 (N/M Forward P/E, -8683.9% operating margin). Growth vs. Quality Trade-Off: ELVN earns the overall head-to-head edge with a stronger Unified Composite Score (35.9/100 SELL vs. DNTH 34.1/100 SELL) and 0.96β · 60% Vol risk profile, whereas DNTH leads top-line expansion (+205.6% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although ELVN compares more favorably head-to-head, both ELVN (35.9/100 SELL) and DNTH (34.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

DNTH leads the Growth & Scale pillar: ELVN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DNTH at +205.6% YoY revenue growth and +0.0% YoY earnings growth on $2.7M TTM revenue (100.0% gross margin, -8683.9% operating margin). On trailing 12-month operating scale, ELVN generates N/A in USD-normalized revenue versus $2.7M for DNTH. In operating R&D and SG&A reinvestment, ELVN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DNTH.

ELVN and DNTH trade at balanced relative valuation multiples. ELVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DNTH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ELVN (-16.8% ROE) versus DNTH (-22.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ELVN carries 46.9% implied volatility (5th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.96β · 60% Vol realized risk). By comparison, DNTH carries 83.5% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.03β · 41% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.